Stockreport

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]

Catalyst Pharmaceuticals, Inc.  (CPRX) 
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.catalystpharma.com
PDF Upon approval, vamorolone would be the first and only treatment option indicated for patients diagnosed with Duchenne muscular dystrophy in Canada The Canadian regula [Read more]